Immunotherapy in cancer continues to advance

Pancreatic cancer is one of the most fatal malignancies, with most patients diagnosed only after the disease has already spread. For those with metastatic cancer, the five-year survival rate sits at just 2–3 percent, and median survival is typically measured in months. A breakthrough study from researchers at UCLA could be a pivotal shift in treatment.Professor Luke O’Neill, Professor of Biochemistry at the School of Immunology, Trinity College brings us the details.